{"filing":{"accession_number":"0001140361-26-040525","cik":"0001133062","ticker":"JANL","company_name":"JANEL CORP","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-16","primary_document":"ef20084224_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133062/000114036126040525/ef20084224_8k.htm"},"events":[{"id":37328,"run_id":34413,"accession_number":"0001140361-26-040525","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Janel Corporation's subsidiary Antibodies Inc. acquired 100% of EnCor Biotechnology Inc. for $11,960,000 in cash plus a $5,040,000 subordinated promissory note. The transaction was funded through operations, credit facility borrowings, and debt issuance, and required amendment to the Senior Credit Facility.","company_name":"JANEL CORP","ticker":"JANL","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":42002,"accession_number":"0001140361-26-040525","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a material acquisition whereby Janel Corporation's subsidiary Antibodies Inc. acquired 100% of EnCor Biotechnology Inc. for $11,960,000 in cash plus a $5,040,000 subordinated promissory note. This is a classic Item 1.01 material acquisition event involving a complete equity purchase of a biotechnology company. The transaction was funded through operations, credit facility borrowings, and debt issuance, and required amendment to the Senior Credit Facility to accommodate the acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42003,"accession_number":"0001140361-26-040525","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 discloses completion of an acquisition or disposition of assets. The section explicitly incorporates by reference Item 1.01 (Entry into a Material Definitive Agreement), indicating a material acquisition or disposition transaction has been completed. This is a core M\u0026A event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37329,"run_id":34413,"accession_number":"0001140361-26-040525","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Janel Corporation amended its senior credit facility to increase borrowing capacity in connection with the EnCor Biotechnology acquisition, representing a material modification to an existing direct financial obligation.","company_name":"JANEL CORP","ticker":"JANL","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":42004,"accession_number":"0001140361-26-040525","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 2.03 discloses an amended loan agreement with a commitment increase under a senior credit facility. This represents a material modification to an existing direct financial obligation—specifically an increase in the borrowing capacity under the company's senior credit facility. The amendment and commitment increase constitute a creation or modification of a direct financial obligation reportable under Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42002,"accession_number":"0001140361-26-040525","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a material acquisition whereby Janel Corporation's subsidiary Antibodies Inc. acquired 100% of EnCor Biotechnology Inc. for $11,960,000 in cash plus a $5,040,000 subordinated promissory note. This is a classic Item 1.01 material acquisition event involving a complete equity purchase of a biotechnology company. The transaction was funded through operations, credit facility borrowings, and debt issuance, and required amendment to the Senior Credit Facility to accommodate the acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"JANEL CORP","ticker":"JANL","filing_date":"2026-10-22"},{"id":42003,"accession_number":"0001140361-26-040525","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 discloses completion of an acquisition or disposition of assets. The section explicitly incorporates by reference Item 1.01 (Entry into a Material Definitive Agreement), indicating a material acquisition or disposition transaction has been completed. This is a core M\u0026A event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"JANEL CORP","ticker":"JANL","filing_date":"2026-10-22"},{"id":42004,"accession_number":"0001140361-26-040525","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 2.03 discloses an amended loan agreement with a commitment increase under a senior credit facility. This represents a material modification to an existing direct financial obligation—specifically an increase in the borrowing capacity under the company's senior credit facility. The amendment and commitment increase constitute a creation or modification of a direct financial obligation reportable under Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T21:02:06.170491+00:00","company_name":"JANEL CORP","ticker":"JANL","filing_date":"2026-10-22"}]}